Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6274182 | 0.82 | GNAI3 (0.41) | TACR1POLB | |
| SCHEMBL17395466 | 0.81 | POLB (0.36) | POLBL3MBTL1 | |
| SCHEMBL605432 | 0.81 | TACR1 (0.37) | TACR1 | |
| SCHEMBL6261069 | 0.79 | TACR1 (0.36) | TACR1 | |
| SCHEMBL23950880 | 0.77 | ATM (0.39) | — | |
| SCHEMBL4969300 | 0.74 | POLB (0.52) | POLBL3MBTL1 | |
| SCHEMBL3832124 | 0.74 | POLB (0.52) | POLBL3MBTL1 | |
| SCHEMBL2462769 | 0.74 | POLB (0.52) | POLBL3MBTL1 | |
| SCHEMBL23926081 | 0.73 | TACR1 (0.36) | TACR1 | |
| SCHEMBL7854892 | 0.73 | TACR1 (0.63) | TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4135844-A1 | FUSED TRICYCLIC KRAS INHIBITORS | Incyte Corporation (US) | 2023-02-22 | — | — | EP | disclosed |
| US-20210355121-A1 | FUSED TRICYCLIC KRAS INHIBITORS | INCYTE CORPORATION | 2021-11-18 | — | — | US | disclosed |
| WO-2021211864-A1 | FUSED TRICYCLIC KRAS INHIBITORS | INCYTE CORPORATION (US) | 2021-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210355121-A1 | FUSED TRICYCLIC KRAS INHIBITORS | KRAS, NRAS, HRAS | TACR1 4660/4885POLB 508/4885L3MBTL1 2314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.